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Background: Lung cancer stem cells (LCSCs) are endowed with high aldehyde dehydrogenase (ALDH) 
expression and play roles in tumor proliferation, metastasis, and drug resistance. Their elusive nature may 
allow them to escape the immune response by tumor-infiltrating lymphocytes (TILs), which can positively 
affect the outcome in non-small cell lung cancer (NSCLC) patients. Despite independent investigations on 
both LCSCs and TILs, the relationship between the two has been very marginally considered. We analyzed 
whether these two cell types may be related as a prerequisite for novel diagnostic and therapeutic approaches.
Methods: In this cross-sectional study, NSCLC human surgical specimens from 12 patients were tested 
by ALDEFLUOR assay to identify ALDHhigh cells. Fluorescence-activated cell sorting (FACS) analyses for 
CD3+, CD4+, and CD8+ TILs were performed in combination with immunohistochemistry evaluation.
Results: Statistically positive correlations were found between ALDH+ and CD8+, and between ALDH+ 
and CD3+ cells populations; no correlation was found between ALDH+ and CD4+ cells. The expression 
of CD3+ and CD8+ by cells accounted for 40.1% and 58.7%, respectively, of the variability of ALDH+ 
cell expression by an R-squared index, which highlights the strong correlation between TILs and LCSCs. 
Immunohistochemistry revealed 6–25% positive cells.
Conclusions: We report a correlation between cytotoxic TILs and LCSCs, which may contribute to the 
future development of targeted therapies focusing on the different roles of lymphocytes against lung cancer.
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cell lung cancer (NSCLC), immunotherapy
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Introduction
Chemotherapy agents generally contain but do not 
totally eliminate tumor cells in non-small cell lung cancer 
(NSCLC) patients (1). This action is also related to a 
subpopulation of cells that can escape from such therapies 
and exhibit lung cancer stem cell (LCSC) characteristics, 
including self-renewal, multiple differentiation and tumor 
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initiation (2). The identification of LCSCs has been the 
subject of several investigations to define their phenotypic 
and biological properties (3,4). Aldehyde dehydrogenase 
(ALDH) activity is an important functional marker of 
normal and malignant stem/progenitor cells (5-9). Cortes-
Dericks et al. (10) showed that the flow cytometry-based 
ALDEFLUOR assay could be used to select ALDHhigh 
and ALDHlow populations to discriminate cancer stem-like 
cell populations from non-cancer stem-like cells. Sullivan 
et al. described an enrichment of cancer stem cells (CSCs) 
in the ALDHhigh population in human NSCLC (11). 
CSCs, supported by the microenvironment, produce more 
differentiated, metastatic cancer cells, which are detected by 
and interact with the immune system. There are three phases 
to this process: elimination, equilibrium and escape (2). 
The prevention of tumor cell growth and innate immunity 
constitute the first line of defense (12). This response 
activates an adaptive immune response against antigens 
that are specifically expressed by lysed tumor cells and leads 
to T cell-dependent tumor control (13). Multiple clinical 
studies demonstrated that the adoptive cell transfer (ACT) 
of autologous tumor-infiltrating lymphocytes (TILs) was 
remarkably effective in melanoma patients (14). Moreover, 
NSCLC shares similarities with melanoma in mutational 
burden and sensitivity to immune checkpoint inhibitors 
(14,15). The presence of TILs positively affects the 
outcome of NSCLC patients (16). The aim of the present 
study is to analyze the relationship between LCSCs isolated 
from human NSCLC patients and CD3+, CD4+ and CD8+ 
TILs. The results may contribute to new perspectives in the 
study of interactions between LCSCs and TILs, prompting 
diagnostic predictive tools and new therapeutic strategies 
for NSCLC treatment.
Methods
This cross-sectional study was carried out in accordance to 
the STROBE (strengthening the reporting of observational 
studies in epidemiology) statement (17).
Collection of tumor specimens
The local Ethics Committee of Modena University Hospital 
approved the present study, which was performed according 
to the guidelines of the Helsinki Convention. Patients 
signed an informed consent, and human lung cancer tissues 
were obtained from 12 consecutive subjects who underwent 
major surgical lung resection between April 2018 and 
September 2018 at the Division of Thoracic Surgery 
of the University Hospital of Modena for stage I, II, or 
IIIA NSCLC [8th tumor, node, metastasis (TNM)] (18). 
Inclusion criteria were: stage I, II, or IIIA NSCLC (8th 
TNM), age between 18 and 85 years, R0 resection, 
availability of formalin-fixed, paraffin-embedded surgery 
specimen from the primary tumor and availability of fresh 
surgical specimen for fluorescence-activated cell sorting 
(FACS) analysis. Exclusion criteria were: incomplete 
resection, unknown TNM status, synchronous tumors, and 
previous lung cancer. The collection of tumor tissues was 
carried out during surgery and was set accordingly with 
the availability of the pathologists involved for our study. 
The tumor tissue was excised only from the primary lung 
nodule. The microscopic features of the cancer cells and 
immunohistochemistry were used to assess the histological 
diagnosis.
Dissociation of primary tissues
Tumor tissues were obtained within 1 to 2 h after surgical 
removal, washed in sterile Dulbecco’s PBS (L1825-BC; 
Merck Millipore, Italy) and mechanically minced into 
small pieces (2 to 4 mm). Minced samples were digested 
using a tumor dissociation kit in a disposable gentle 
MACS™ C-Tube (Miltenyi Biotec, Italy) according to the 
manufacturer’s instructions. Samples were digested for 
60 min at 37 ℃ in a gentle MACS Octo dissociator, filtered 
through 70-μm sterile cell strainers, centrifuged at 300 ×g 
for 5 min, and resuspended in a DMEM and Ham’s F12 
media mixture (2:1) (Gibco, USA) containing 50 IU/mL 
penicillin-streptomycin and 4 mM glutamine. Viable cells 
were counted using an optic phase-contrast microscope.
ALDEFLUOR assay
Single-cell suspensions of primary tumor cells were diluted 
in ALDEFLUOR assay buffer containing BODIPY-
aminoacetaldehyde (STEMCELL Technologies, Vancouver, 
BC, Canada). The assay was performed according to the 
manufacturer’s protocol. Briefly, at least 5,000,000 tumor 
cells were resuspended in ALDEFLUOR BUFFER 
(5 μL/106) and stained with ALDEFLUOR substrate. 
Immediately, 5×105 cells were transferred to a control tube 
containing 5 μL of diethylaminobenzaldehyde (DEAB), 
which is a specific inhibitor of ALDH. Control and test 
samples were incubated for 45 min at 37 ℃ and protected 
from light. Cells were centrifuged at 300 ×g for 5 min. 
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The cell pellet was resuspended in 1 mL of ALDEFLUOR 
assay buffer. Cell morphology was evaluated using side 
scatter (SSC) and forward scatter (FSC). Dead cells were 
excluded using 7-amino-actinomycin D (7-AAD) staining. 
Cell sorting and ALDH analyses were performed using 
a FACSAria III (Becton Dickinson, Franklin Lakes, NJ, 
USA). The results were analyzed using FACSDiva software 
(Becton Dickinson, Franklin Lakes, NJ, USA). The gating 
strategy included the ALDHhigh gate, which was set at least 
one log apart from the ALDHlow gate. Sorted cells were 
directly lysed for gene expression analyses.
FACS analysis of lymphocytic markers
Primary tumor cell suspensions were stained with 
phycoerythrin (PE)-conjugated anti-human CD3 
(B ioLegend,  San  Diego ,  CA,  USA) ,  f luoresce in 
isothiocyanate (FITC)-conjugated anti-human CD4 
(BioLegend), and allophycocyanin (APC)-conjugated anti-
human CD8 (BioLegend). An isotype control sample for 
each condition was used to exclude the autofluorescence 
background. Dead cells were excluded using 7-AAD 
staining. Lymphocytes were gated on CD3+ cellular 
elements, and helper or cytotoxic T cells were distinguished 
based on the sole expression of the CD4 or CD8 marker, 
respectively (Figure 1). Analyses were performed using a 
FACSAria III by the same operator, who previously had 
shared measurement techniques with other operators. Data 
were analyzed using FACSDiva software.
Immunohistochemistry
Slides for eight patients were deparaffinized with xylene, 
rehydrated in a graded alcohol series, and washed in PBS 
twice for five minutes each. The sections were heated in 
10 mM sodium citrate buffer, pH =6.0, for 15 min in a 
95 ℃ water bath for antigen retrieval. PBS washes (5 min 
each) were performed until the buffer cooled. Endogenous 
Figure 1 Gating strategy on CD3+ cellular elements and helper or cytotoxic T cells. Lymphocytes were distinguished based on their CD4 
or CD8 expression. SSC, side scatter; FSC, forward scatter; 7-AAD, 7-amino-actinomycin D; PE, phycoerythrin; APC, allophycocyanin, 
FITC, fluorescein isothiocyanate.
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peroxidase activity was blocked via incubation in 3% H2O2 
at room temperature for 10 min. Blocking serum was added 
in a dropwise manner at room temperature for 20 min 
to reduce the nonspecific background. Samples were 
incubated with the anti-CD3, CD4, and CD8 antibodies 
(Ventana Medical System, USA) overnight at 4 ℃. Sections 
were washed in PBS three times for 2 min and incubated 
with a biotinylated secondary antibody (PK-4001; Vector 
Labs, USA) for 30 min at room temperature. The slides 
were subsequently incubated with ABC-HRP (PK-
4001; Vector Labs, USA) for 30 min, washed in PBS, and 
stained with 3,3-diaminobenzidine (DAB). Sections were 
counterstained with Mayer’s hematoxylin, dehydrated, and 
mounted. Images were collected using a Zeiss Axioskop 
microscope with a Zeiss AxioCam ICc 3 High-Resolution 
Microscope Camera. Tissue sections were examined at 
10× magnification to characterize the overall staining 
pattern and at 20× magnification for a more accurate 
evaluation of the cells to assign the appropriate values. Two 
independent investigators who were blinded to the patients’ 
clinicopathological characteristics performed the scoring 
of the CD3+, CD4+, and CD8+ staining according to a 
previously updated scoring system for colon cancer (19). 
Sections were scored independently. Immunoreactivity of 
CD3, CD4, and CD8 was evaluated using a semiquantitative 
method based on the positivity of the tumor cells as follows: 
(I) no or sporadic (approximately 0–5%); (II) moderate 
(approximately 6–25%); (III) abundant (approximately 26–
50%); and (IV) highly abundant (approximately >50%) (19).
Statistical analyses
No formal sample size estimation was carried out in this 
study, and the number of patients included in the analyses 
was only based on resource availability. Enrolled patients 
were those who satisfied the inclusion and exclusion criteria 
in a time period of 6 months.
Continuous variables were expressed as the means ± 
standard deviations and ranges, and categorical variables 
were expressed as absolute and percentage frequencies. 
Comparisons between subgroups were performed using the 
Wilcoxon-Mann-Whitney test for numerical variables.
The outcome variables of interest were (I) ALDH+ 
expression; (II) CD3+ expression; (III) CD4+ expression; 
and (IV) CD8+ expression. The measurements of ALDH+ 
and TILs expression used for the analyses were the 
percentages of cells calculated based on the total number 
of 7-AAD-negative cells. The three parameters of interest 
were the correlations between: (I) ALDH+ and CD3+ 
expression; (II) ALDH+ and CD4+ expression; and (III) 
ALDH+ and CD8+ expression (20). Correlations were 
assessed using Pearson’s linear correlation and Spearman’s 
rank correlation coefficients. We considered two cell 
populations to be correlated when both linear and rank 
correlations were observed. The proportion of explained 
variability for each of the three correlations of interest was 
also measured by using the R-squared index and is reported 
as a percentage.
All statistical analyses were carried out in accordance 
with recently published guidelines (20) and were performed 
using R 3.4.3 software (The R Foundation for Statistical 
Computing, Wien, Austria) at the P<0.05 significance level.
Results
Patients’ characteristics
Surgical specimens were obtained from 12 patients, 
which were all included in the study. The major clinical 
and demographic characteristics of the study samples 
are reported in Table 1. The average age was 71.1 years, 
83.3% of patients were male and all patients were smokers. 
Clinical stage I was observed in 16.7% of patients, stage 
II was observed in 33.3% of patients, and stage III was 
observed in 50% of patients. Nine patients (75.0%) had 
adenocarcinoma, and 3 patients (25.0%) had squamous cell 
carcinoma of the lung.
The expression of CD3+, CD4+ and CD8+ cells 
as determined by FACS is described in Table 1. CD3 
expression appeared on 10.8% of cells (range, 1.0–25.7%). 
CD4 was significantly more expressed than CD8 (5.3% 
with range 0.2–18.6% and 3.2% with range 0.5–10.9%, 
respectively). ALDH, CD3, CD4, and CD8 expression was 
also investigated in subgroups of patients: by gender (males 
of females), age (≥75, <75), histotype (adenocarcinoma, 
squamous cell carcinoma) and stage (I–II, III) (Table 2). 
There were no relevant differences in the expression of 
these markers in the analyzed subgroups (Table 2).
Correlation between ALDH+ cells and lymphocyte subsets
Correlation analyses between ALDH+ and CD3+ cells 
measured by FACS analysis are reported in Table 3 and 
Figure 2. We observed a moderate-to-high positive linear 
correlation (Pearson’s correlation =0.63, 95% CI: 0.09–
0.89, P=0.0270) and a moderate-to-high positive rank 
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correlation (Spearman’s correlation =0.67, P=0.0204). The 
proportion of explained variability was 40.1%. Neither 
linear [Pearson’s correlation =0.34, 95% confidence interval 
(CI): –0.29 to 0.76, P=0.2802] nor rank-based (Spearman’s 
correlation =0.36, P=0.2560) correlation was found for 
ALDH+ and CD4+ cells (Figure 3). The proportion of 
Table 1 Descriptive characteristics of the study patients
Features
All patients (n=12)
Mean ± SD/n Range/%
Patient characteristics
Age, years 71.1±9.2 52–84
Gender, male 10 83.3
Smoker, yes 12 100.0
Adenocarcinoma 9 75.0
Squamous cell carcinoma 3 25.0
Stage I 2 16.7
Stage II 4 33.3
Stage III 6 50.0
FACS analysis, %
ALDH+ 4.6±3.8 0.7–12.5
CD3+ 10.8±9.1 1.0–25.7
CD4+ 5.3±5.7 0.2–18.6
CD8+ 3.2±3.0 0.5–10.9
Immunohistochemistry by CD3, CD4, CD8 (15) (n=8)
CD3+
No or sporadic 1 12.5
Moderate 6 75.0
Abundant 1 12.5
CD4+
No or sporadic 2 25.0
Moderate 5 62.5
Abundant 1 12.5
CD8+
No or sporadic 4 50.0
Moderate 4 50.0
Abundant 0 0
SD, standard deviation; FACS, fluorescence-activated cell 
sorting.
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Table 3 Correlation analysis between ALDH+ cells and CD3+, CD4+ and CD8+ cells
Antigen
Pearson linear correlation Spearman rank correlation
Explained variability (%)
r 95% CI P r P
CD3+ 0.63 0.09–0.89 0.0270 0.67 0.0204 40.1
CD4+ 0.34 –0.29 to 0.76 0.2802 0.36 0.2560 11.5
CD8+ 0.77 0.34–0.93 0.0036 0.72 0.0110 58.7
r, correlation coefficient; P, P value; CI, confidence interval.
explained variability was 11.5%. Analyses of the correlations 
between ALDH+ and CD8+ cells are reported in Table 3 
and Figure 4. We observed highly positive linear and 
rank correlations (Pearson’s correlation =0.77, 95% CI: 
0.34–0.93, P=0.0036 and Spearman’s correlation =0.72, 
P=0.0110). The proportion of explained variability was 
58.7%. Taken together, all of these data indicate that CD3+ 
and CD8+ cells were correlated with ALDH+ cells.
Immunohistochemistry
The expression patterns of T lymphocyte-associated 
markers (CD3, CD4, and CD8) were evaluated in NSCLC 
tumor sections (Figure 5). Cell positivity was scored in 
4 classes, as reported (15), and the results are reported in 
Table 1. The most frequent class for all of the analyzed 
Figure 2 ALDH+ cells compared with CD3+ cells. Scatter plot of 
ALDH+ cells and CD3+ expression.
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Figure 3 ALDH+ cells compared with CD4+ cells. Scatter plot of 
ALDH+ cells and CD4+ expression.
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Figure 4 ALDH+ cells compared with CD8+ cells. Scatter plot of 
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markers was class 2 (moderate). We observed that the 
quantification of CD3+ and CD4+ also reached class 3 
(abundant), and the quantification of CD8+ was greatest in 
class 2 (moderate) (Table 1), indirectly confirming the data 
from FACS analyses.
Discussion
In the present study, we originally observed a relationship 
between LCSCs and TILs in NSCLC samples obtained 
from affected patients. First, we found a positive correlation 
between ALDH+ cells and CD3+ cells and an even stronger 
correlation between ALDH+ cells and cytotoxic CD8+ 
lymphocytes. The fact that CD3+ and CD8+ expression 
accounted for 40.1% and 58.7%, respectively, of the 
variability of ALDH expression highlights a relevant 
relationship between these cell populations.
Regarding the role of these lymphocytes, CD3 is the 
surface marker of mature T cells and is used to detect both 
T helper and T cytotoxic cells with antitumor activity. 
Thus, CD3+ cells play a potential dual role in lung cancer 
via the support of host defense and tumor progression. In 
contrast, the CD8+ T lymphocyte subpopulation exhibits 
only cytotoxic activity against cancer cells and may play an 
important role in antitumor immunity (21). The importance 
of CD8+ was investigated and clarified in the setting of 
predictors of clinical outcomes in tumors, including the 
analysis of their origin, their functional classification, 
their molecular markers and underlying mechanisms of 
action against tumors. Clarifications of CD8+ roles could 
be important to further explorations in the scenarios of 
prevention, diagnosis and clinical treatment of malignant 
diseases (21-23). CD8+ effector and T regulatory (Treg) 
CD8+ cells maintain normal homeostasis in cancer, and 
Figure 5 Immunohistochemical analysis and quantification of CD3-, CD4-, and CD8-positive cells in human lung cancer. Paraffin-
embedded human lung cancer tissues were stained with CD3, CD4 and CD8 antibodies to detect T lymphocytes. (A) Quantification of 
CD3+ cells in lung cancer; (B) quantification of CD4+ cells in lung cancer; (C) quantification of CD8+ cells in lung cancer. Semiquantitative 
method based on the positivity of the tumor cells as follows: (I) no or sporadic (approximately 0–25%); (II) moderate (approximately 26–
50%); (III) abundant (approximately 51–75%); (IV) highly abundant (approximately >75%). Representative images of human lung sections 
stained with antibodies based on their pathology are shown. Scale bar =100 μm.
100 μm 100 μm
100 μm
CD3A
CD4B CD8C
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the ratio CD8+/Treg acts as a predictor of clinical outcome 
in many tumors, such as squamous cell carcinoma of the 
cervix (24), colorectal cancer (25) and breast cancer (26). 
The CD8+/Treg ratio was also a potential predictor of 
response to immunotherapy in mouse models of pancreatic 
cancer (27), which further supports its potential as an 
important biomarker and even a driver of the response to 
immunotherapy. Recent clinical studies are encouraging, 
showing that immunotherapy for lung cancer alone or in 
combination with conventional treatments significantly 
improves patient outcomes (27). However, the exact 
immune cell composition in NSCLC is not clear, and the 
scientific community is focusing their attention on specific 
intratumoral cell compositions that are represented by 
TILs (24). For the first time to our knowledge, this study 
raises the attention on the relationship between TILs and 
a specific lung cancer cell subset. Specifically, LCSCs may 
also generate unexplored biological insights that may lead to 
innovative diagnostic strategies for NSCLC in the context 
of immunotherapy. The reason for this correlation would 
require deeper investigations and may apparently argue 
against studies demonstrating an association between high 
levels of TILs and improved recurrence-free survival in stage 
1a NSCLC patients and a reduced likelihood of systemic 
recurrence (27-29). In addition, a higher frequency of 
TILs within large node-negative NSCLC correlates with a 
decreased risk of disease recurrence and improved disease-
free survival (30). Thus, the relationship between high levels 
of LCSCs, linked with tumor relapse and metastasis (31), and 
high levels of CD8+ cells could be apparently contradictory.
Indeed, our study suggests an interplay of CD8+ cells 
and CSCs, indicating that CD8+ T cells could be crucial 
for cell-mediated antitumor immune response. It has 
been reported that CSCs express several tumor-associated 
antigens that could be recognized by CD8+ cytotoxic 
lymphocytes (32). Possible explanations of the positive 
correlation detected in our analysis may be that the CSCs 
stimulate the immune system to initiate a cytotoxic immune 
response, mediated by CD8+, to suppress these CSCs (32).
However, in our study, we reported no correlation 
between CSCs and CD4+ cells. We believe that these 
data reflect what has been previously described in the 
literature for solid tumors (27-35), defining additional 
roles for CD4+ T cells, some of which are independent 
of other lymphocytes, that influence and/or contribute to 
tumor immunity during carcinogenesis. Consequently, our 
findings may underline the dualistic role of CD4+ T cells 
in antitumor activity (33). In fact, the absence of correlation 
between CD4+ T cells and CSCs shown in our data seems 
to highlight a “mild equilibrium” between these two 
populations, in which the tumor may have the possibility to 
grow. 
One notable aspect of our study is that CD4+ and CD8+ 
lymphocytes interplay with LCSCs in the same manner as 
previously described for epithelial lung cancer cells (29-30).
Limitations
The main limitations of our study include the low number 
of patients due to resource availability, the difficulty in 
obtaining surgical specimens and the small quantity of 
LCSCs available. In particular, the low sample size could 
have caused insufficient statistical power; moreover, we 
were not able to control for potential confounders with a 
multivariable analysis. However, our research is the first 
attempt towards showing a correlation between TILs and 
LCSCs in NSCLC. Further investigations are needed to 
confirm these data in a larger cohort of patients and to 
provide more detailed insight on the relationship between 
TILs and CSCs, such as their joint effect on patient 
survival. Our research also has the limitation that we did 
not characterize CD4+ cell subpopulations; however, our 
results suggest that CD4+ cells seemed to be involved 
independently of LCSCs in the immune response against 
cancer, while CD8+ cells showed a direct dependence on 
LCSCs.
Conclusions
In conclusion, in our study, we showed a significant positive 
correlation between CD8+ T cells and LCSCs, which 
may prospectively contribute to the development of more 
immuno-therapeutic approaches for NSCLC patients by 
targeting CSCs and improving their sensitivity against 
the cytotoxic activity of CD8+ lymphocytes. Moreover, 
we strongly believe that even the absence of correlation 
between CD4+ lymphocytes and CSCs needs to be further 
investigated. Further, elucidating the mechanisms and 
interactions among these subpopulations may contribute to 
the future development of targeted therapies focusing on 
the different roles of lymphocytes against lung cancer.
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